KR860006984A - 서방성 제제의 제조방법 - Google Patents

서방성 제제의 제조방법 Download PDF

Info

Publication number
KR860006984A
KR860006984A KR1019860001609A KR860001609A KR860006984A KR 860006984 A KR860006984 A KR 860006984A KR 1019860001609 A KR1019860001609 A KR 1019860001609A KR 860001609 A KR860001609 A KR 860001609A KR 860006984 A KR860006984 A KR 860006984A
Authority
KR
South Korea
Prior art keywords
unit
physiologically active
active substance
release
insoluble polymer
Prior art date
Application number
KR1019860001609A
Other languages
English (en)
Other versions
KR930007245B1 (ko
Inventor
무네오 후꾸이
무네오 후꾸이 (외 7)
코우지 도무로
시게루 마수야마
아쑤시 카지야마
다미오 히꼬사까
마사요시 아루가
요시아끼 소에이시
사부로 히구찌
Original Assignee
야마노우찌 세이야꾸 가부시끼 가이샤
모리오까 시게오
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=12739832&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR860006984(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 야마노우찌 세이야꾸 가부시끼 가이샤, 모리오까 시게오 filed Critical 야마노우찌 세이야꾸 가부시끼 가이샤
Publication of KR860006984A publication Critical patent/KR860006984A/ko
Application granted granted Critical
Publication of KR930007245B1 publication Critical patent/KR930007245B1/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

내용 없음

Description

서방성 제제의 제조방법
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
제1도 및 제2도는 각기 본 발명의 서방성 복수단위 제제(정제)를 인체에 경구 투여후, 혈장중에서 시간경과에 따른 생리학적 활성 물질(YM-12617)의 농도 변화를 나타내는 그래프. 제3도는 본 발명의 서방성 복수 단위 제제(캡슐)를 비글개에 경구투여 후, 혈장 중에서 시간 경과에 따른 생리학적 활성 물질(YM-12617)의 농도변화를 나타내는 그래프.

Claims (10)

  1. 생리학적 활성물질 및 단위중량을 기준하여 최소한 50중량%의 단위-형성 물질을 혼합시키고 이 혼합물에 방출 조절제를 가한 후, 수득되는 혼합물을 과립화시킴을 특징으로 하여, 생리학적 활성물질을 서서히 방출시키는 약제학적 서방성 개별단위 제제를 제조하는 방법.
  2. 제1항에 있어서, 단위-형성물질이 결정성 셀룰로즈인 방법.
  3. 제1항에 있어서, 방출조절제가 수불용성 고분자물질의 수성현탁액, 이의 수성유제 또는 이의 함수유기용매 용액인 방법.
  4. 제3항에 있어서, 수불용성 고분자물질이 메타크릴산-에틸 아크릴레이트 코폴리머 또는 에틸 셀룰로즈인 방법.
  5. 제1항에 있어서, 방출조절제가 물인 방법.
  6. 제1항에 있어서, 단위-형성 물질이 결정성 셀룰로즈이고, 방출 조절제가 수불용성 고분자물질의 수성현탁액, 이의 수성유제 또는 이의 함수 유기용매 용액인 방법.
  7. 제6항에 있어서, 수불용성 고분자물질이 메타크릴산-에틸 아크릴레이트 코폴리머 또는 에틸 셀룰로즈인 방법.
  8. 제1 내지 7항에 있어서, 생리학적 활성 물질이 5-{2-[2-(o-에톡시페녹시)에틸아미노]프로필}-2-메톡시벤젠설폰아미드 염산염 [YM-12617]인 방법.
  9. 제1항에 있어서, 생리학적 활성물질이 5-{2-[2-(o-에톡시페녹시)에틸아미노]프로필}-2-메톡시벤젠 설폰아미드 염산염이고, 단위 형성물질이 결정성 셀룰로즈이며, 방출조절제가 메타크릴산-에틸아크릴레이트 코폴리머 또는 에틸 셀룰로즈인 방법.
  10. 생리학적 활성물질 및 단위 중량을 기준하여 최소한 50중량%의 단위 형성물질을 혼합시키고 이 혼합물에 방출조절제를 가한 후, 수득되는 혼합물을 과립화시키고, 상기 과립을 정제화 또는 캡슐화 시킴을 특징으로 하여, 생리학적 활성물질을 서서히 방출시키는 약제학적 서방성 복수단위제제를 제조하는 방법.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019860001609A 1985-03-08 1986-03-07 서방성 제제의 제조방법 KR930007245B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP46,180 1985-03-08
JP4618085 1985-03-08
JP46180 1997-02-28

Publications (2)

Publication Number Publication Date
KR860006984A true KR860006984A (ko) 1986-10-06
KR930007245B1 KR930007245B1 (ko) 1993-08-04

Family

ID=12739832

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019860001609A KR930007245B1 (ko) 1985-03-08 1986-03-07 서방성 제제의 제조방법

Country Status (8)

Country Link
US (1) US4772475A (ko)
EP (2) EP0533297B1 (ko)
JP (1) JPH0772129B2 (ko)
KR (1) KR930007245B1 (ko)
CA (1) CA1264293A (ko)
DE (2) DE3650657D1 (ko)
ES (1) ES8800041A1 (ko)
ZA (1) ZA861565B (ko)

Families Citing this family (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4690487A (en) * 1983-11-14 1987-09-01 Allied Corporation Hermetically sealed fiber optic connector
NL8500724A (nl) * 1985-03-13 1986-10-01 Univ Groningen Inrichtingen voor geregelde afgifte van werkzame stoffen, alsmede werkwijze ter vervaardiging daarvan.
GB8618811D0 (en) * 1986-08-01 1986-09-10 Approved Prescription Services Sustained release ibuprofen formulation
US5129877A (en) * 1988-04-29 1992-07-14 University Of Georgia Research Foundation, Inc. Receptor-mediated delivery system
US5169642A (en) * 1988-06-24 1992-12-08 Abbott Laboratories Sustained-release drug dosage units
US5268182A (en) * 1988-06-24 1993-12-07 Abbott Laboratories Sustained-release drug dosage units of terazosin
US5028433A (en) * 1988-11-30 1991-07-02 Banyu Pharmaceutical Co., Ltd. Readily absorbable drug formulation of NB-818
US5258186A (en) * 1989-03-10 1993-11-02 Yamanouchi Pharmaceutical Co., Ltd. Drug release controlling coating material for long acting formulations
DE69001734T2 (de) * 1989-09-04 1993-09-02 Yamanouchi Pharma Co Ltd Aeusserlich anzuwendende amusulosin enthaltende arzneizubereitung.
CA2034171A1 (en) * 1990-01-22 1991-07-23 Gorm Wagner Method of treating erectile dysfunction
US5175003A (en) * 1990-04-06 1992-12-29 Biosytes Usa, Inc. Dual mechanism controlled release system for drug dosage forms
EP0533799B1 (en) * 1990-06-20 1995-10-18 Advanced Polymer Systems, Inc. Compositions and methods for the controlled release of soluble active substances
US5102668A (en) * 1990-10-05 1992-04-07 Kingaform Technology, Inc. Sustained release pharmaceutical preparation using diffusion barriers whose permeabilities change in response to changing pH
US5968551A (en) 1991-12-24 1999-10-19 Purdue Pharma L.P. Orally administrable opioid formulations having extended duration of effect
US6602861B1 (en) * 1992-04-16 2003-08-05 Research Corporation Technologies, Inc. Acylated phospholipid drugs
US5376384A (en) * 1992-12-23 1994-12-27 Kinaform Technology, Inc. Delayed, sustained-release pharmaceutical preparation
IL109460A (en) 1993-05-10 1998-03-10 Euro Celtique Sa Controlled release formulation comprising tramadol
IL110014A (en) 1993-07-01 1999-11-30 Euro Celtique Sa Solid controlled-release oral dosage forms of opioid analgesics
US7740881B1 (en) 1993-07-01 2010-06-22 Purdue Pharma Lp Method of treating humans with opioid formulations having extended controlled release
US5879705A (en) * 1993-07-27 1999-03-09 Euro-Celtique S.A. Sustained release compositions of morphine and a method of preparing pharmaceutical compositions
KR100354702B1 (ko) 1993-11-23 2002-12-28 유로-셀티크 소시에떼 아노뉨 약학조성물의제조방법및서방형조성물
US5891471A (en) 1993-11-23 1999-04-06 Euro-Celtique, S.A. Pharmaceutical multiparticulates
US5843480A (en) 1994-03-14 1998-12-01 Euro-Celtique, S.A. Controlled release diamorphine formulation
GB9505032D0 (en) 1995-03-13 1995-05-03 Westminster Lab Ltd Improvements in or relating to organic compositions
GB9422154D0 (en) 1994-11-03 1994-12-21 Euro Celtique Sa Pharmaceutical compositions and method of producing the same
US5965161A (en) 1994-11-04 1999-10-12 Euro-Celtique, S.A. Extruded multi-particulates
GB9519363D0 (en) 1995-09-22 1995-11-22 Euro Celtique Sa Pharmaceutical formulation
US5773031A (en) * 1996-02-27 1998-06-30 L. Perrigo Company Acetaminophen sustained-release formulation
GB9710699D0 (en) * 1997-05-24 1997-07-16 Danbiosyst Uk Gastro-retentive controlled release system
SE9702338D0 (sv) * 1997-06-18 1997-06-18 Astra Ab An analytical method and industrial process including the same
TW536402B (en) * 1998-06-26 2003-06-11 Yamanouchi Pharma Co Ltd Pharmaceutical composition for the therapy of voiding dysfunction
US6806294B2 (en) 1998-10-15 2004-10-19 Euro-Celtique S.A. Opioid analgesic
DE19918325A1 (de) 1999-04-22 2000-10-26 Euro Celtique Sa Verfahren zur Herstellung von Arzneiformen mit regulierter Wirkstofffreisetzung mittels Extrusion
US10179130B2 (en) 1999-10-29 2019-01-15 Purdue Pharma L.P. Controlled release hydrocodone formulations
MXPA02004293A (es) 1999-10-29 2002-10-31 Euro Celtique Sa Formulaciones de hidrocodona de liberacion controlada..
CN100518827C (zh) 2000-10-30 2009-07-29 欧罗赛铁克股份有限公司 控释氢可酮制剂
WO2002036077A2 (en) * 2000-11-06 2002-05-10 Andrx Pharmaceuticals, Inc. Once a day antihistamine and decongestant formulation
UA81224C2 (uk) 2001-05-02 2007-12-25 Euro Celtic S A Дозована форма оксикодону та її застосування
US20110104214A1 (en) 2004-04-15 2011-05-05 Purdue Pharma L.P. Once-a-day oxycodone formulations
RU2245136C2 (ru) * 2001-07-27 2005-01-27 Яманоути Фармасьютикал Ко., ЛТД Композиция, включающая тонкодисперсные частицы с замедленным высвобождением для быстроразлагающихся в щечной полости таблеток, и способ ее получения
HUP0401978A3 (en) * 2001-11-07 2008-07-28 Synthon Bv Tamsulosin tablets
JP4625637B2 (ja) 2002-02-22 2011-02-02 シャイア エルエルシー 活性物質送達系及び活性物質を保護し投与する方法
EA008377B1 (ru) * 2002-04-24 2007-04-27 Бёрингер Ингельхайм Фарма Гмбх Унд Ко. Кг Фармацевтическая комбинация для лечения доброкачественной гиперплазии простаты или для долговременной профилактики острой ишурии
US7018658B2 (en) * 2002-11-14 2006-03-28 Synthon Bv Pharmaceutical pellets comprising tamsulosin
KR100592512B1 (ko) * 2002-11-22 2006-07-03 서울약품공업(주) 탐술로신 또는 약제학적으로 허용되는 이의 염을활성성분으로 하는 서방성 배뇨장애 치료제
CN1758903A (zh) * 2003-01-27 2006-04-12 安斯泰来制药有限公司 坦洛新或其盐的肠缓释微粒及其制造方法
US20040253309A1 (en) * 2003-01-27 2004-12-16 Yamanouchi Pharmaceutical Co., Ltd. Enteric sustained-release fine particles of tamsulosin and its salt and manufacturing method thereof
WO2005013960A1 (en) * 2003-08-12 2005-02-17 Kyungdong Pharm. Co., Ltd. Preparing method for controlled released type tablet tamsulosin hcl and the tablet thereof
JP2005104914A (ja) * 2003-09-30 2005-04-21 Kyowa Yakuhin Kogyo Kk 塩基性薬剤含有製剤
KR100436701B1 (ko) * 2003-11-07 2004-06-22 주식회사 씨티씨바이오 염산 탐스로신 함유 방출 조절형 제제 및 그의 제조방법
US8128958B2 (en) * 2003-11-10 2012-03-06 Astellas Pharma Inc. Sustained release pharmaceutical composition
US8197846B2 (en) * 2003-11-10 2012-06-12 Astellas Pharma Inc. Sustained release pharmaceutical composition
US20050106253A1 (en) * 2003-11-13 2005-05-19 Platteeuw Johannes J. Pharmaceutical pellets comprising tamsulosin
SI21637A (sl) * 2003-12-23 2005-06-30 LEK farmacevtska dru�ba d.d. Farmacevtska oblika z nadzorovanim sproščanjem
KR100582350B1 (ko) * 2004-02-17 2006-05-22 한미약품 주식회사 탐수로신 염산염의 경구투여용 조성물 및 이의 서방성과립 제제
US20050186275A1 (en) * 2004-02-23 2005-08-25 Standard Chem. & Pharm. Co. Ltd. Sustained release tamsulosin formulations
KR100681660B1 (ko) * 2004-03-17 2007-02-09 주식회사종근당 방출제어 펠릿의 약제학적 조성물
US7491263B2 (en) 2004-04-05 2009-02-17 Technology Innovation, Llc Storage assembly
EP1618873B1 (de) * 2004-07-14 2007-06-06 Siegfried Generics International AG Granulat zur kontrollierten Freisetzung von Tamsulosin, enthaltend Alginat
US7238839B2 (en) * 2004-10-07 2007-07-03 Divi's Laboratories Limited Process for the resolution of racemic (R,S) -5-(2-(2-(2- ethoxyphenoxy) ethylamino)Propyl)-2-methoxybenzene sulfonamide (tamsulosin), its novel R and S isomers and their salts and processes for their preparation
JP2008523143A (ja) * 2004-12-13 2008-07-03 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド 月経困難症の治療のためのα−アドレナリン遮断剤の使用
US20090208579A1 (en) * 2004-12-27 2009-08-20 Eisai R & D Management Co., Ltd. Matrix Type Sustained-Release Preparation Containing Basic Drug or Salt Thereof, and Method for Manufacturing the Same
EP1830886B1 (en) 2004-12-27 2016-04-13 Eisai R&D Management Co., Ltd. Method for stabilizing anti-dementia drug
JP2006232696A (ja) * 2005-02-23 2006-09-07 Taisho Pharm Ind Ltd 徐放性製剤
CN101166543B (zh) * 2005-04-28 2014-07-16 卫材R&D管理有限公司 含抗痴呆药物的组合物
EP2026766A1 (en) * 2006-05-17 2009-02-25 Synthon B.V. Tablet composition with a prolonged release of tamsulosin
AU2007275034A1 (en) * 2006-07-21 2008-01-24 Lab International Srl Hydrophilic abuse deterrent delivery system
US20080113030A1 (en) * 2006-11-09 2008-05-15 Ching-Fen Hsiao Sustained release tamsulosin formulations
US20090004284A1 (en) * 2007-06-26 2009-01-01 Watson Pharmaceuticals, Inc. Controlled release tamsulosin hydrochloride formulation
CA2709103C (en) 2007-12-13 2017-01-17 Vanda Pharmaceuticals Inc. Method and composition for treating an alpha adrenoceptor-mediated condition
PL2222300T3 (pl) 2007-12-13 2015-02-27 Vanda Pharmaceuticals Inc Sposób i skład preparatu do leczenia chorób z udziałem receptorów serotoniny
WO2009112874A1 (en) * 2008-03-10 2009-09-17 Eurodrug Laboratories B.V. Modified release composition comprising doxofylline
US8529953B2 (en) * 2008-07-01 2013-09-10 Sawai Pharmaceutical Co., Ltd. Process for production of spherical microparticles comprising tamsulosin hydrochloride
US8465770B2 (en) * 2008-12-24 2013-06-18 Synthon Bv Low dose controlled release tablet
WO2012110092A1 (en) 2011-02-17 2012-08-23 Synthon Bv Tamsulosin derivatives
WO2013045352A1 (de) 2011-09-30 2013-04-04 Basf Se Verfahren zur herstellung von festen pigmenthaltigen filmüberzugsmitteln in form von granulaten auf basis von magensaftresistenten filmbildnern für pharmazeutische dosierungsformen
CN105229924B (zh) * 2013-05-21 2018-11-13 日本碍子株式会社 压电设备及其制造方法、以及压电自立基板的制造方法
CN105073100A (zh) 2013-06-21 2015-11-18 沃克哈特有限公司 坦索罗辛或其盐的药物组合物
BR102013020508B1 (pt) 2013-08-12 2021-01-12 Ems S/A. Forma de dosagem que compreende um inibidor de esteroide 5-alfa-redutase e um bloqueador alfa, processo para a preparaçãode uma forma de dosagem e uso da forma de dosagem
ES2555485T1 (es) 2014-05-26 2016-01-04 Galenicum Health S.L. Composiciones farmacéuticas que contienen un agente activo
CA2936748C (en) 2014-10-31 2017-08-08 Purdue Pharma Methods and compositions particularly for treatment of attention deficit disorder
CZ2015225A3 (cs) 2015-03-30 2016-10-12 Zentiva, K.S. Nový krok ve způsobu potahování pelet obsahujících Tamsulosin.HCI
KR101879133B1 (ko) 2017-07-11 2018-07-17 (주)동구바이오제약 비뇨기 질환 예방 또는 치료용 제제 및 이의 제조방법
EP3473244A1 (en) 2017-10-20 2019-04-24 Veru Inc. Controlled release oral tamsulosin hydrochloride
EP3473245A1 (en) 2017-10-20 2019-04-24 Veru Inc. Controlled release oral tamsulosin hydrochloride
KR101957694B1 (ko) 2018-05-28 2019-03-13 (주)동구바이오제약 비뇨기 질환 예방 또는 치료용 제제 및 이의 제조방법
JP7370125B2 (ja) * 2018-11-09 2023-10-27 日本化薬株式会社 エルロチニブを有効成分とする医薬錠剤
JP7370124B2 (ja) * 2018-11-09 2023-10-27 日本化薬株式会社 エルロチニブを有効成分とする医薬錠剤
US10722473B2 (en) 2018-11-19 2020-07-28 Purdue Pharma L.P. Methods and compositions particularly for treatment of attention deficit disorder

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB630439A (en) * 1945-09-11 1949-10-13 Ethan Allan Brown Improvements in or relating to pharmaceutical preparations
DE1467781A1 (de) * 1963-07-15 1968-12-05 Boehringer Sohn Ingelheim Verfahren zur Herstellung von Dragees mit verlaengerter Wirkstofffreigabe
DE1962016C3 (de) * 1969-12-11 1979-11-08 Uzina De Medicamente Bucuresti, Bukarest Verfahren zur Herstellung von Tabletten mit protrahierter Wirkung
CA952431A (en) * 1970-09-28 1974-08-06 Frank M. Bardani Controlled release medicament
FR2183546B1 (ko) * 1972-05-10 1975-06-20 Servier Lab
JPS50131867A (ko) * 1974-04-08 1975-10-18
HU173438B (hu) * 1975-11-27 1979-05-28 Chinoin Gyogyszer Es Vegyeszet Sposob poluchenija novykh proizvodnykh 4-okso-1,6,7,8-/tetragidro-4h-pirido/1,2/pirimidina s zaderzhivajuhhejj vozgoranie aktivnot'ju i protivosvertivajuhhem effektom
US4495189A (en) * 1975-11-27 1985-01-22 Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara R.T. Condensed pyrimidines
JPS535112A (en) * 1976-03-08 1978-01-18 Santen Pharmaceutical Co Ltd New cysteine derivatives
JPS5332111A (en) * 1976-09-07 1978-03-27 Asahi Chem Ind Co Ltd Composition for tablet
DD137186A1 (de) * 1978-06-30 1979-08-22 Guenther Magister Verfahren zur herstellung von rieselfaehigen produkten aus zellulosepulver
JPS6011888B2 (ja) * 1978-10-11 1985-03-28 参天製薬株式会社 リウマチ疾患治療薬
JPS55153715A (en) * 1979-05-18 1980-11-29 Nikken Kagaku Kk Prolonged granule of theophylline
JPS56110665A (en) * 1980-02-08 1981-09-01 Yamanouchi Pharmaceut Co Ltd Sulfamoyl-substituted phenetylamine derivative and its preparation
JPS6056122B2 (ja) * 1980-05-21 1985-12-09 塩野義製薬株式会社 徐放性製剤
JPS574921A (en) * 1980-06-13 1982-01-11 Chugai Pharmaceut Co Ltd Remedy for cardiovascular disorder
US4469704A (en) * 1980-12-26 1984-09-04 Ss Pharmaceutical Co., Ltd. 2,3-Butanediol diester derivatives, process for producing the same, and an antiulcer drug containing the same
JPS58189114A (ja) * 1982-04-30 1983-11-04 Ss Pharmaceut Co Ltd 抗潰瘍剤
US4552765A (en) * 1982-05-14 1985-11-12 Santen Pharmaceutical Co., Ltd. Aletheine derivatives
US4489026A (en) * 1982-09-07 1984-12-18 The Upjohn Company Process for preparing solid unit dosage forms of ultra-low dose drugs
JPS59190913A (ja) * 1983-04-14 1984-10-29 Eisai Co Ltd ケノデオキシコ−ル酸含有顆粒剤
JPS6036410A (ja) * 1983-08-08 1985-02-25 Unitika Ltd 生分解性薬物供与体の製造方法
EP0187703B1 (en) * 1985-01-11 1992-08-05 Teijin Limited Sustained release preparation

Also Published As

Publication number Publication date
EP0533297A1 (en) 1993-03-24
ES8800041A1 (es) 1987-10-16
DE3688532D1 (de) 1993-07-15
DE3650657D1 (de) 1998-01-02
DE3688532T2 (de) 1993-09-23
EP0194838A3 (en) 1988-02-03
EP0194838A2 (en) 1986-09-17
ZA861565B (en) 1986-10-29
JPH0772129B2 (ja) 1995-08-02
ES552794A0 (es) 1987-10-16
EP0194838B1 (en) 1993-06-09
KR930007245B1 (ko) 1993-08-04
CA1264293A (en) 1990-01-09
US4772475A (en) 1988-09-20
EP0533297B1 (en) 1997-11-19
JPS629A (ja) 1987-01-06

Similar Documents

Publication Publication Date Title
KR860006984A (ko) 서방성 제제의 제조방법
US4462982A (en) Microcapsules and method of preparing same
CA1208559A (en) Pharmaceutical mixture
FI94923C (fi) Menetelmä nestemäisen annostelumuodon valmistamiseksi farmaseuttisesti aktiivisen aineen oraalista antoa varten
KR880004804A (ko) 분무건조 아세트 아미노펜
Murthy et al. Current perspectives on the dissolution stability of solid oral dosage forms
ATE217188T1 (de) Granulierte pharmazeutische zusammensetzung
BRPI0721654A2 (pt) formas de dosagem sàlida compreendendo um revestimento entÉrico com liberaÇço acelerada do fÁrmaco
JPS59128323A (ja) ７〜１０のｐＫａおよび１５〜１００ｇ／水１ｍｌの水溶解度をもつ薬品の一定放出速度の固体経口調剤配合物
PT86536B (pt) Processo para a preparacao de um sistema terapeutico para ingredientes activos pouco soluveis compreendendo um involucro, um nuclio e uma passagem atraves do involucro
KR890009377A (ko) 방출 조절된 카비도파/레보도파 배합물
NO175405C (no) Fremgangsmåte for fremstilling av et farmasöytisk preparat med sakte frigivelse, som ikke er et injeksjonsfluid
JPS6111933B2 (ko)
KR900013943A (ko) 장기작용성 제제용 약제-방출 조절 피복물질
PT85819B (pt) Processo para a preparacao de membranas de revestimento e de composicoes farmaceuticas obtidas a partir delas
YU71894A (sh) Novi farmaceutski preparat sa difuziono-osmotskom kontrolom oslobađanja leka i postupak za dobivanje istog
KR930003905A (ko) 약학적 결합 제제
EP0136103B1 (en) Amosulalol hydrochloride long acting formulations
KR870000069A (ko) 안정한 고체 제형의 제조 방법
PT96921B (pt) Dispositivo de libertacao intermitente
KR910004184A (ko) 마이크로캡슐화된 미각-차폐된 수불용성 nsaid약제
KR910007517A (ko) 기초의약제 히드로클로라이드의 서방성 제제
ATE206042T1 (de) Verfahren zur herstellung von niedrigdosierten arzneimitteln
KOMATSU et al. Biopharmaceutical evaluation of gelatin microcapsules of sulfonamides
AU661726B2 (en) Peroral drug delivery system

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
G160 Decision to publish patent application
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20050722

Year of fee payment: 13

EXPY Expiration of term